Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biovica International publ : will present at the Biomarkers & Precision Medicine Congress in San Diego

share with twitter share with LinkedIn share with facebook
share via e-mail
10/03/2019 | 02:46am EST

The 4th Annual Biomarkers & Precision Medicine Congress will be arranged October 8-9 in San Diego, USA. With increased focus on precision medicine follows a need to translate scientific progress into patient benefits through personalized healthcare. The focus of the Biomarker Congress is the discovery and clinical development of biomarkers and Biovica has been invited to present DiviTum®. The congress includes presentations, case studies and panel discussions with participants from global pharmaceutical and biotech companies, as well as academic institutions.

At the conference, Pontus Nobréus will address how liquid biomarkers can contribute with fundamental information and to a more effective process in the development of oncology drugs. DiviTum® is a cell proliferation biomarker and a valuable tool for cancer researchers and drug developers when evaluating cell-cycle regulating compounds like the new CDK4/6 inhibitors and pipeline drugs. The use of novel biomarkers, such as DiviTum®, provides key information during the drug development continuum, saves time and costs, can increase the probability for regulatory success and shorten time to market.

"I look forward to attend the congress and present DiviTum® to this audience of professionals. I will highlight the unique data we have with DiviTum® as a tool for effective pre-clinical evaluation of candidate drug effects all the way to large clinical trials demonstrating the unique capability of DiviTum® to provide accurate prognosis and quick evaluation of cell-cycle regulating drugs. With increased focus on targeted therapies, there is a need for good biomarkers, and I am excited to be invited to the congress to contribute to the discussion regarding biomarkers in oncology drug development and clinical validation" says Pontus Nobréus, Business Development Director Biovica.

"The Biomarker congress is an excellent opportunity for us to engage with the pharmaceutical industry and highlight how DiviTum® can contribute to a more effective drug development process and be a useful tool for management of new targeted oncology therapies, supporting our aim to improve cancer patients outcome" says Anders Rylander, CEO Biovica.

Link for more information about the congress:


For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Read more: www.biovica.com




(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
01/16BIOVICA INTERNATIONAL PUBL : Clinical Cancer Research publishes results supporti..
2019BIOVICA INTERNATIONAL PUBL : strengthens management team
2019Q2 INTERIM REPORT : Work with the FDA application progressing as planned
2019Q2 INTERIM REPORT :  Work with the FDA application progressing as planned
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
2019BIOVICA INTERNATIONAL PUBL : DiviTum - Strong prognostic marker in operable brea..
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
2019BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
2019BIOVICA ISO 13485 : 2016 certificate renewal
2019BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
More news
Financials (SEK)
Sales 2020 4,60 M
EBIT 2020 -29,0 M
Net income 2020 -36,0 M
Finance 2020 26,0 M
Yield 2020 -
P/E ratio 2020 -11,3x
P/E ratio 2021 -79,1x
EV / Sales2020 83,5x
EV / Sales2021 18,5x
Capitalization 410 M
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Average target price 23,10  SEK
Last Close Price 17,40  SEK
Spread / Highest target 32,8%
Spread / Average Target 32,8%
Spread / Lowest Target 32,8%
EPS Revisions
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors